Amgen resolves patent suit, squashing Teva's neutropenia biosimilar until 2013
19 July 2011
Nancy Faigen
Please Login to read the full article.
19 July 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- European generics firms, squeezed between innovators and payers, seek diversity
- Australian panel recommends transparency overhaul at TGA
- Generics firms urge EC to help boost sales in EU and emerging markets
- Lupin seeds research accord with Medicis while settling Solodyn dispute
